Sarepta Therapeutics, Inc. financial data

Symbol
SRPT on Nasdaq
Industry
Pharmaceutical Preparations
Location
215 First Street, Suite 415, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
AVI BIOPHARMA INC (to 7/12/2012), ANTIVIRALS INC (to 5/12/1998)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 393 % -17%
Quick Ratio 66 % +58.3%
Debt-to-equity 228 % -39.5%
Return On Equity 11.8 %
Return On Assets 3.61 %
Operating Margin 4.94 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 95.5M shares +2.11%
Common Stock, Shares, Outstanding 95.5M shares +2.09%
Common Stock, Value, Issued 10K USD +11.1%
Weighted Average Number of Shares Outstanding, Basic 95.4M shares +7.31%
Weighted Average Number of Shares Outstanding, Diluted 100M shares +13%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.64B USD +48.5%
Revenue from Contract with Customer, Excluding Assessed Tax 1.51B USD +49.1%
Costs and Expenses 1.56B USD +3.66%
Operating Income (Loss) 81M USD
Nonoperating Income (Expense) 48.4M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 129M USD
Income Tax Expense (Benefit) 7.56M USD -74%
Net Income (Loss) Attributable to Parent 122M USD
Earnings Per Share, Basic 1.59 USD/shares
Earnings Per Share, Diluted 1.57 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 198M USD -63.5%
Cash, Cash Equivalents, and Short-term Investments 1.69B USD -15.8%
Accounts Receivable, after Allowance for Credit Loss, Current 435M USD +36.3%
Inventory, Net 566M USD +132%
Other Assets, Current 165M USD +7.15%
Assets, Current 2.69B USD +9.57%
Property, Plant and Equipment, Net 306M USD +44%
Operating Lease, Right-of-Use Asset 141M USD +5.58%
Other Assets, Noncurrent 83.6M USD -39%
Assets 3.6B USD +15.8%
Accounts Payable, Current 119M USD +35.1%
Employee-related Liabilities, Current 57.1M USD +11.7%
Accrued Liabilities, Current 345M USD +6.97%
Contract with Customer, Liability, Current 127M USD +465%
Liabilities, Current 699M USD +55.2%
Contract with Customer, Liability, Noncurrent 325M USD -33%
Operating Lease, Liability, Noncurrent 170M USD +26.2%
Other Liabilities, Noncurrent 1M USD
Liabilities 2.38B USD +1.43%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.25M USD
Retained Earnings (Accumulated Deficit) -4.37B USD +2.71%
Stockholders' Equity Attributable to Parent 1.22B USD +59.8%
Liabilities and Equity 3.6B USD +15.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -242M USD -15.6%
Net Cash Provided by (Used in) Financing Activities 22.1M USD -78.3%
Net Cash Provided by (Used in) Investing Activities 219M USD +1651%
Common Stock, Shares Authorized 198M shares 0%
Common Stock, Shares, Issued 95.5M shares +2.09%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.14M USD +98.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 213M USD -62%
Interest Paid, Excluding Capitalized Interest, Operating Activities 7.19M USD +2.35%
Deferred Tax Assets, Valuation Allowance 897M USD
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 912M USD +10.8%
Operating Lease, Liability 159M USD +117%
Payments to Acquire Property, Plant, and Equipment 32.4M USD +242%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 125M USD
Lessee, Operating Lease, Liability, to be Paid 399M USD +292%
Property, Plant and Equipment, Gross 418M USD +27.1%
Operating Lease, Liability, Current 17.8M USD +15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 34.5M USD +66.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 33.7M USD +60.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +12%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 240M USD +738%
Lessee, Operating Lease, Liability, to be Paid, Year Three 28M USD +82.8%
Deferred Tax Assets, Operating Loss Carryforwards 155M USD -35.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 3.33M shares 0%
Unrecognized Tax Benefits 65M USD +5.39%
Lessee, Operating Lease, Liability, to be Paid, Year Four 28M USD +232%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 11.1M USD
Current Federal Tax Expense (Benefit) 4.18M USD
Amortization of Intangible Assets 2.57M USD +163%
Depreciation, Depletion and Amortization 8.74M USD -22.7%
Share-based Payment Arrangement, Expense 180M USD -3.68%
Interest Expense 19.2M USD -18.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%